BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...microenvironment, thereby limiting systemic toxicity. Safety data from an ongoing Phase I study of the IL-12...
BioCentury | Nov 19, 2020
Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

...Staff Writer Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12...
...to deliver therapeutics that stay localized at the injection site. Lead candidate exoIL-12 displays functional IL-12...
...I/II testing for advanced solid tumors. Data are expected in mid-2021. TARGETSIL-12Interleukin-12 Danielle Golovin exoIL-12 exoSTING Codiak BioSciences Inc. Interleukin-12 (IL-12) Prostaglandin...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...MK-3475, lambrolizumab) Tavo, tavokinogene telseplasmid (DNA IL-12, ImmunoPulse IL-12...
BioCentury | Oct 2, 2020
Distillery Therapeutics

IL-12B monomers to treat multiple sclerosis, rheumatoid arthritis

...monomer reduced disease scores, paw swelling and paw thickness, and improved locomotor activity.TARGET/MARKER/PATHWAY: Interleukin-12B (IL-12B); interleukin-12 receptor...
...Aug. 19, 2020doi:10.1073/pnas.2000653117CONTACT: Kalipada Pahan, Rush University Medical Center, Chicago, Ill.email: kalipada_pahan@rush.edu Sandi Wong Rush University Medical Center Interleukin-12B (IL-12B) Interleukin-12 receptor...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...the biology and technology behind next-gen IL-2, IL-12...
...antigen. Chief among these Th1-promoting cytokines are IL-12...
...Therapeutics Inc. links cytokines including IL-2 and IL-12...
BioCentury | Aug 18, 2020
Deals

Dragonfly’s TrinKET-enhancing cytokine platform sees early win with $475M BMS deal

...another deal with BMS for nearly half a billion dollars up front covering a clinical IL-12...
...designed so other combination agents can be added. Initial data are expected in the fall.While IL-12...
...– Interleukin-12 PD-1 (PDCD1; CD279) – Programmed cell death 1 Elizabeth S. Eaton Bristol Myers Squibb Co. Dragonfly Therapeutics Inc. Interleukin-12 (IL-12)...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...technology from the Massachusetts Institute of Technology. The newco’s lead program combines two cytokines -- IL-12...
...Inc. (NASDAQ:SRPT) in 2019. Hongjiang Li contributed to this report. Targets IL-2 Interleukin-2 IL-12 - Interleukin-12...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...hematological tumors. Cox told BioCentury that this cell therapy, and a preclinical candidate tethered to IL-12...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...first program, SENTI-101, which comprises mesenchymal stem cells that home to ovarian tumors and produce IL-12...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...then evaluated in combinations. Clackson said the B round will also go toward advancing Xilio’s IL-12...
...Targets CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 IL-2 - Interleukin-2 IL-12 - Interleukin-12...
Items per page:
1 - 10 of 571